Chronic HDV occurs only with HBV and confers markedly higher risks of rapid progression, cirrhosis, liver failure, and ...

Positioning shifts from treatment to prophylaxis, using vaccines to blunt antimicrobial resistance-driven unmet need and mitigate infection-associated long-term morbidity, including neurological ...

Talent and leadership culture convert finance into a strategic asset, emphasizing judgment under uncertainty and the ...

Harpreet Singh, MD, touches on how the Commissioner’s National Priority Voucher program is accelerating regulatory review timelines without fundamentally changing how pivotal trials are designed.

Sales concentration follows a Pareto dynamic, but the exceptionally large eligible GLP-1 population inflates risk-adjusted ...

Reputation influences whether regulators, payers, clinicians, talent, and communities accelerate progress or impose friction, ...

Kevin Dondarskit of Deloitte Consulting discusses the risks that drug makers face if they decide to put too much focus on an area where they may lack expertise, such as the emerging GLP-1 market. A ...

Makary’s departure followed internal disputes over approval decisions and Covid-19 vaccine posture, catalyzing a rapid ...

Dr. Richard Graham explains how FDA’s new program allows for the usage of real-time data during clinical trials. In April, ...

The Incyte–Genesis deal pairs significant upfront capital with long-tail milestones and royalties, while granting Incyte ...

Regeneron and Parabilis Medicines partner to discover and develop antibody-Helicon conjugates, aiming to create a new class ...